Scarica l'app Stockscreener
12.94
2.54%
0.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Northern Trust Corp Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Dimensional Fund Advisors LP Sells 271,156 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Viridian Therapeutics (VRDN) to Release Quarterly Earnings on Wednesday - Defense World
Q2 EPS Estimate for Viridian Therapeutics Lowered by Analyst - Defense World
Wedbush Boosts Earnings Estimates for Viridian Therapeutics - Defense World
Q2 EPS Estimate for Viridian Therapeutics Reduced by Analyst - Defense World
B. Riley Boosts Earnings Estimates for Viridian Therapeutics - Defense World
Needham & Company LLC Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 - The AM Reporter
JMP Securities Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $38.00 - Defense World
Royal Bank of Canada Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $45.00 - Defense World
Q1 Earnings Estimate for VRDN Issued By HC Wainwright - Defense World
Needham & Company LLC Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 - Defense World
The Goldman Sachs Group Issues Pessimistic Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - Defense World
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) - BioSpace
Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus
What 5 Analyst Ratings Have To Say About Viridian Therapeutics - Benzinga
FDA Grants Breakthrough Therapy Status to Viridian's (VRDN) Veligrotug | VRDN Stock News - GuruFocus
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) | VRDN Stock News - GuruFocus
Viridian Therapeutics (VRDN) Target Price Adjusted by RBC Capita - GuruFocus
Goldman Sachs Adjusts Price Target for VRDN, Maintains Buy Ratin - GuruFocus
Goldman Sachs Adjusts Price Target for VRDN, Maintains Buy Rating | VRDN Stock News - GuruFocus
Viridian Therapeutics (VRDN) Price Target Update by JMP Securities | VRDN Stock News - GuruFocus
Viridian Therapeutics (VRDN) Price Target Reduced Amid Market Concerns | VRDN Stock News - GuruFocus
Needham Maintains Buy Rating on Viridian Therapeutics (VRDN) | V - GuruFocus
Needham Maintains Buy Rating on Viridian Therapeutics (VRDN) | VRDN Stock News - GuruFocus
Viridian Therapeutics price target lowered to $38 from $42 at Citizens JMP - TipRanks
Thyroid Eye Disease Market Top Companies StudyHorizon - openPR.com
Bullish Viridian Therapeutics Insiders Loaded Up On US$616.3k Of Stock - simplywall.st
Viridian Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Viridian Therapeutics (VRDN) Sees Price Target Adjustment by Citizens JMP | VRDN Stock News - GuruFocus
Viridian Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Viridian Therapeutics: Strong Financials and Promising Pipeline Justify Buy Rating - TipRanks
Viridian Therapeutics Inc (VRDN)’s Market Momentum: Closing Strong at 13.12, Down -3.67 - DWinneX
Stifel maintains Buy on Viridian Therapeutics, $41 target By Investing.com - Investing.com India
Viridian Therapeutics Shares Fall After Q1 Net Loss Widens, Revenue Flat - marketscreener.com
Viridian Therapeutics shares fall as Q1 loss narrows, revenue beats By Investing.com - Investing.com Nigeria
Viridian Therapeutics shares fall as Q1 loss narrows, revenue beats - Investing.com
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Viridian Therapeutics, Inc.\DE SEC 10-Q Report - TradingView
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results - BioSpace
Viridian Therapeutics Q1 2025 Financial Results - TradingView
Earnings Flash (VRDN) Viridian Therapeutics Posts Q1 Net Loss $0.87 a Share, vs. FactSet Est of $1 Loss - marketscreener.com
How to Take Advantage of moves in (VRDN) - news.stocktradersdaily.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq L - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VRDN Stock News - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Inc [NASDAQ: VRDN] Sees Increase in Stock Value - knoxdaily.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharma - Barchart.com
Viridian Therapeutics Inc (VRDN) did well last session? - uspostnews.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Barclays PLC - Defense World
Upward Trajectory: Viridian Therapeutics Inc (VRDN) Posts a Gaine, Closing at 13.53 - DWinneX
Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $35.70 - Defense World
HC Wainwright Reiterates Buy Rating for Viridian Therapeutics (NASDAQ:VRDN) - Defense World
Viridian Therapeutics Inc [VRDN] Shares Fall -1.82 % on Wednesday - knoxdaily.com
How did Viridian Therapeutics Inc (VRDN) fare last session? - uspostnews.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by JPMorgan Chase & Co. - Defense World
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):